These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1210 related articles for article (PubMed ID: 25439688)

  • 1. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
    Donker M; van Tienhoven G; Straver ME; Meijnen P; van de Velde CJ; Mansel RE; Cataliotti L; Westenberg AH; Klinkenbijl JH; Orzalesi L; Bouma WH; van der Mijle HC; Nieuwenhuijzen GA; Veltkamp SC; Slaets L; Duez NJ; de Graaf PW; van Dalen T; Marinelli A; Rijna H; Snoj M; Bundred NJ; Merkus JW; Belkacemi Y; Petignat P; Schinagl DA; Coens C; Messina CG; Bogaerts J; Rutgers EJ
    Lancet Oncol; 2014 Nov; 15(12):1303-10. PubMed ID: 25439688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
    Galimberti V; Cole BF; Zurrida S; Viale G; Luini A; Veronesi P; Baratella P; Chifu C; Sargenti M; Intra M; Gentilini O; Mastropasqua MG; Mazzarol G; Massarut S; Garbay JR; Zgajnar J; Galatius H; Recalcati A; Littlejohn D; Bamert M; Colleoni M; Price KN; Regan MM; Goldhirsch A; Coates AS; Gelber RD; Veronesi U;
    Lancet Oncol; 2013 Apr; 14(4):297-305. PubMed ID: 23491275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
    Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A;
    Lancet Oncol; 2018 Oct; 19(10):1385-1393. PubMed ID: 30196031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
    Tinterri C; Canavese G; Gatzemeier W; Barbieri E; Bottini A; Sagona A; Caraceni G; Testori A; Di Maria Grimaldi S; Dani C; Boni L; Bruzzi P; Fernandes B; Scorsetti M; Zambelli A; Gentile D;
    Br J Surg; 2023 Aug; 110(9):1143-1152. PubMed ID: 37471574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.
    Bartels SAL; Donker M; Poncet C; Sauvé N; Straver ME; van de Velde CJH; Mansel RE; Blanken C; Orzalesi L; Klinkenbijl JHG; van der Mijle HCJ; Nieuwenhuijzen GAP; Veltkamp SC; van Dalen T; Marinelli A; Rijna H; Snoj M; Bundred NJ; Merkus JWS; Belkacemi Y; Petignat P; Schinagl DAX; Coens C; van Tienhoven G; van Duijnhoven F; Rutgers EJT
    J Clin Oncol; 2023 Apr; 41(12):2159-2165. PubMed ID: 36383926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).
    van Roozendaal LM; de Wilt JH; van Dalen T; van der Hage JA; Strobbe LJ; Boersma LJ; Linn SC; Lobbes MB; Poortmans PM; Tjan-Heijnen VC; Van de Vijver KK; de Vries J; Westenberg AH; Kessels AG; Smidt ML
    BMC Cancer; 2015 Sep; 15():610. PubMed ID: 26335105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
    Krag DN; Anderson SJ; Julian TB; Brown AM; Harlow SP; Costantino JP; Ashikaga T; Weaver DL; Mamounas EP; Jalovec LM; Frazier TG; Noyes RD; Robidoux A; Scarth HM; Wolmark N
    Lancet Oncol; 2010 Oct; 11(10):927-33. PubMed ID: 20863759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
    de Boniface J; Filtenborg Tvedskov T; Rydén L; Szulkin R; Reimer T; Kühn T; Kontos M; Gentilini OD; Olofsson Bagge R; Sund M; Lundstedt D; Appelgren M; Ahlgren J; Norenstedt S; Celebioglu F; Sackey H; Scheel Andersen I; Hoyer U; Nyman PF; Vikhe Patil E; Wieslander E; Dahl Nissen H; Alkner S; Andersson Y; Offersen BV; Bergkvist L; Frisell J; Christiansen P; ;
    N Engl J Med; 2024 Apr; 390(13):1163-1175. PubMed ID: 38598571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
    Wang SL; Fang H; Song YW; Wang WH; Hu C; Liu YP; Jin J; Liu XF; Yu ZH; Ren H; Li N; Lu NN; Tang Y; Tang Y; Qi SN; Sun GY; Peng R; Li S; Chen B; Yang Y; Li YX
    Lancet Oncol; 2019 Mar; 20(3):352-360. PubMed ID: 30711522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital.
    Ogiya A; Kimura K; Nakashima E; Sakai T; Miyagi Y; Iijima K; Morizono H; Makita M; Horii R; Akiyama F; Iwase T
    Breast Cancer; 2016 Mar; 23(2):318-22. PubMed ID: 25376341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of the axilla in breast cancer: evidences and unresolved issues].
    Fodor J; Polgár C; Péley G; Németh G
    Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is axillary lymph node clearance required in node-positive breast cancer?
    Bundred NJ; Barnes NL; Rutgers E; Donker M
    Nat Rev Clin Oncol; 2015 Jan; 12(1):55-61. PubMed ID: 25367714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.
    Leiter U; Stadler R; Mauch C; Hohenberger W; Brockmeyer N; Berking C; Sunderkötter C; Kaatz M; Schulte KW; Lehmann P; Vogt T; Ulrich J; Herbst R; Gehring W; Simon JC; Keim U; Martus P; Garbe C;
    Lancet Oncol; 2016 Jun; 17(6):757-767. PubMed ID: 27161539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary treatment for operable primary breast cancer.
    Bromham N; Schmidt-Hansen M; Astin M; Hasler E; Reed MW
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004561. PubMed ID: 28052186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative analysis of the correlation between axillary treatment and upper limb lymphedema].
    Lin Y; Xu Y; Zhang XH; Wang CJ; Sun Q
    Zhonghua Wai Ke Za Zhi; 2019 Sep; 57(9):713-716. PubMed ID: 31474063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
    Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
    JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
    Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
    Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.